OvaScience, Inc. (OVAS) Milestone Rewards Option Bulls

OvaScience Inc's (OVAS) Augment fertility treatment produced its first birth

by Alex Eppstein

Published on May 7, 2015 at 2:55 PM
Updated on Jun 24, 2020 at 10:16 AM

OvaScience Inc (NASDAQ:OVAS) traders have been buying to open calls at a breakneck pace recently. The fertility stock's 10-day call/put volume ratio across the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) is 8.13. In other words, more than eight OVAS calls have been bought to open for every put over the last two weeks.

Elsewhere on the Street, 100% of analysts tracking the security rate it a "strong buy." What's more, OVAS' consensus 12-month price target of $64 represents a 148.6% premium to the current price of $25.74-- as well as never-before-charted waters.

Today's strong price action is vindicating these optimists. At last check, OVAS shares were 4.8% higher, after the company's Augment fertility treatment produced its first-ever birth. Longer term, though, the picture isn't so rosy. OvaScience Inc (NASDAQ:OVAS) has plunged 41.5% year-to-date.

A Schaeffer's 39th Anniversary Exclusive!

8 Top Stock Picks for 2020

Access your FREE insider report before it's too late!


  
 
 

Partnercenter